Significantly Reduced the Size of Nasal Polyps, as Measured by Bilateral Endoscopic Nasal Polyp Score (NPS) at Weeks 24 (Coprimary Endpoint) and 52 (Key Secondary Endpoint) in SINUS-521

Illustrations of endoscopy adapted from actual
patient images.

-2.24
IMPROVEMENT

IN NPS AT WEEK 52 with DUPIXENT 300 mg Q2W + INCS (n=150) (baseline score 6.07) vs 0.15 worsening with placebo + INCS (n=153) (baseline score 5.96) (LSM difference: -2.40 [95% CI: -2.77, -2.02]) in SINUS-522

-1.71
IMPROVEMENT

IN NPS AT WEEK 24 with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) (baseline score 6.18) vs 0.10 worsening with placebo + INCS (n=153) (baseline score 5.96) (LSM difference -1.80 [95% CI: -2.10, -1.51]) in SINUS-522

  • NPS improved as early as Week 4 (LSM difference vs placebo: -1.15 [95% CI: -1.40, -0.91]) in SINUS-522
-1.89
IMPROVEMENT

IN NPS AT WEEK 24 with DUPIXENT 300 mg Q2W + INCS (n=143) (baseline score 5.64) vs 0.17 worsening with placebo + INCS (n=133) (baseline score 5.86) (LSM difference: -2.06 [95% CI: -2.43, -1.69]) in SINUS-241

Nasal polyp score (NPS), the sum of right and left nostril scores (range 0 to 8) as evaluated by nasal endoscopy: reduced score
indicates improvement.

see snot-22 results

Back to lmk-ct results

Explore the Safety Data and Study Designs

View Safety Data SEE THE FULL STUDY DESIGNS

Dosage and
Administration
See the recommended dosing and
administration options for patients
on DUPIXENT.
EXPLORE ADMINISTRATION OPTIONS